Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer

Summary

The purpose of this study is to determine whether S-1 is effective as 2nd line therapy in slowing tumor activity in patients with metastatic pancreatic cancer who have previously received 1st line treatment with a gemcitabine regimen. The study is also looking at the safety of S-1.

Timeline

Start

2005-06

Primary completion

2007-06

Completion

2007-10

Drugs

Indications